Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board
Adaptimmune, the T cell therapy company pioneering engineered T cell receptors for the treatment of cancer and infectious disease, has appointred Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect. Dr Knowles succeeds Nicholas Cross who has been Chairman of the company since foundation and will remain on the Board as Deputy Chairman.
Adaptimmune was established in 2008 to develop unique T cell receptor engineering technology for adoptive T cell therapy through a proprietary platform co-owned with its sister company, Immunocore. Adaptimmune already has clinical trials in progress in HIV, multiple myeloma, melanoma and sarcoma and most recently opened a Phase I/IIa clinical trial in ovarian cancer in the US to investigate the safety and efficacy of treating patients with their own T cells that have been genetically engineered to enhance their anti-tumour properties.
Dr Knowles has been a Non-Executive Director of Adaptimmune since 2011 and was formerly President of Group Research and a Member of the Executive Committee at F.Hoffman-La Roche Ltd, Basel, Switzerland for 12 years. Dr Knowles also served as a Board member at Genentech Inc. for more than 10 years and was a Member of the Board of Chugai Pharmaceuticals, Tokyo, Japan. Prior to joining Roche, he was Research Director, Glaxo Wellcome Europe.
Dr Knowles has also served as Chairman of the Hever Group and the EFPIA research Directors Group. He was instrumental in creating the Innovative Medicines Initiative (IMI) and was the first Chairman of the Board of IMI (a 2 Billion Euro Joint Undertaking with the EU Commission). He is a Distinguished Professor (FiDiPro) at the University of Helsinki, Finland, holds a visiting chair at the University of Oxford, and is a visiting scholar of Pembroke College, Cambridge.
James Noble, Chief Executive Officer of Adaptimmune, commented: “We are delighted that Jonathan has agreed to serve as the executive Chairman of Adaptimmune. His extensive experience across the pharmaceutical industry and academia will be particularly valuable as we expand our existing clinical programmes and prepare to open additional clinical trials in further cancer indications.
“I would like to acknowledge the significant commitment and input from Nick Cross to Adaptimmune as our founding Chairman during the past 5 years. He played a key role in the formation of Adaptimmune and in securing the funding for the company since then. His support and guidance have been instrumental in enabling us to make such rapid progress in development and we are pleased that he will continue to serve as Deputy Chairman.”
Dr Knowles said: “It is a pleasure to be appointed as the new chairman of Adaptimmune. I have been impressed by the significant progress that the company has already made, with multiple programmes under way in the clinic. I am delighted to have the opportunity to work more closely with the Adaptimmune team to bring breakthrough cancer therapies and potential cures to patients.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance